Mankind Pharma Limited manufactures pharmaceutical products for antibiotic, antifungal, NSAIDs, gastrointestinal, anthelmintic, cardiovascular, dermal, erectile dysfunction, and other categories. It also offers contraceptive products, over-the-counter medicines, pregnancy detection cards, artificial sweeteners, and other products; and nutritional supplements, cosmetics, anti-infective tablets, anti-diabetic tablets, proton pump inhibitors, anti-allergic tablets, emergency contraceptives, anti-emetic, and other products. In addition, the company provides active pharmaceutical ingredients for various therapeutic areas, such as cardiology, respiratory, neurology, gastroenterology, diabetology, ...
236, Okhla Industrial Estate
New Delhi, 110 020
Founded in 1991
Mankind Pharma to Invest INR 1.5 Billion in Construction of Nutraceutical Factory in India
Oct 16 15
Mankind Pharma has invested some INR 1.5 billion ($23 million) on the development of a manufacturing plant in Paonta Sahib.
Two Funds Are Reportedly In Talks To Buy Mankind Stake
May 14 15
ChrysCapital may sell its eight-year-old investment in Mankind Pharma Limited at a price that is nearly 10 times the value of its original investment. Capital International, Inc. (Capital International Private Equity Funds) and Warburg Pincus LLC are in the final stages of negotiation with ChrysCapital to buy its 11% stake in Mankind Pharma, according to two people familiar with the development. The deal size is estimated at around $225 million-$250 million, they said. “ChrysCapital has received serious pre-emptive offers from a couple of global PE funds that have been forwarded to the Juneja family, promoters of Mankind Pharma. As Fund-IV comes to an end, it is true that ChrysCapital is in talks with the Junejas to provide an exit for their investment in Mankind latest by the end of calendar year 2015,” said Sanjiv Kaul, managing director, ChrysCapital. ChrysCapital has appointed Ernst & Young (EY) and Avendus Capital Private Limited as bankers for the transaction, according to the first person cited above. The process will be completed by August 2015-September 2015, he said. Spokespeople for Warburg Pincus and Capital International declined to comment citing company policy, reported Mint, and Mankind declined to comment on the stake sale in an email, saying the company’s “spokesperson is travelling”.
Mankind Pharma Keen to Spend INR 5 Billion for Expansion in Local Market
Apr 11 15
Mankind Pharmaceuticals is ready to invest around INT 5 billion to acquire local pharma companies in order to strengthen its presence in the domestic market. The pharma company is not the sole candidate in this race as almost all the leading Indian pharma majors are adopting the same measure for their expansion.